<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-07-23T20:21:49Z</responseDate><request verb="GetRecord" identifier="oai:repisalud.isciii.es:20.500.12105/22822" metadataPrefix="mets">https://repisalud.isciii.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:repisalud.isciii.es:20.500.12105/22822</identifier><datestamp>2024-09-10T13:10:37Z</datestamp><setSpec>com_20.500.12105_15322</setSpec><setSpec>com_20.500.12105_2051</setSpec><setSpec>col_20.500.12105_16967</setSpec></header><metadata><mets xmlns="http://www.loc.gov/METS/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="&#xa;&#x9;&#x9;&#x9;&#x9;DSpace_ITEM_20.500.12105-22822" TYPE="DSpace ITEM" PROFILE="DSpace METS SIP Profile 1.0" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd" OBJID="&#xa;&#x9;&#x9;&#x9;&#x9;hdl:20.500.12105/22822">
   <metsHdr CREATEDATE="2026-07-23T22:21:49Z">
      <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
         <name>Repisalud</name>
      </agent>
   </metsHdr>
   <dmdSec ID="DMD_20.500.12105_22822">
      <mdWrap MDTYPE="MODS">
         <xmlData xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
            <mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Gomez-Lobon, Ana</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Serrano Lopez De Las Hazas, Joaquin</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Fanjul, Francisco</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Rovira Torres, Pilar</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Vanrell Ballestero, Ana</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Payeras Cifre, Antonio</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Riera, Melchor</mods:namePart>
               </mods:name>
               <mods:extension>
                  <mods:dateAccessioned encoding="iso8601">2024-09-10T13:10:37Z</mods:dateAccessioned>
               </mods:extension>
               <mods:extension>
                  <mods:dateAvailable encoding="iso8601">2024-09-10T13:10:37Z</mods:dateAvailable>
               </mods:extension>
               <mods:originInfo>
                  <mods:dateIssued encoding="iso8601">2019</mods:dateIssued>
               </mods:originInfo>
               <mods:identifier type="citation">Gomez-Lobon A, Lopez Hazas J Serrano, Fanjul F, Rovira Torres P, Vanrell Ballesteros A, Payeras Cifre A, et al. Effectiveness of antiretroviral therapy in treatment-naive patients. Results at 24 and 48 weeks. HIV AIDS Rev. 2019;18(2):100-6.</mods:identifier>
               <mods:identifier type="doi">10.5114/hivar.2019.86374</mods:identifier>
               <mods:identifier type="e-issn">1732-2707</mods:identifier>
               <mods:identifier type="issn">1730-1270</mods:identifier>
               <mods:identifier type="journal">HIV &amp; AIDS Review</mods:identifier>
               <mods:identifier type="other">http://hdl.handle.net/20.500.13003/17268</mods:identifier>
               <mods:identifier type="pui">L2002428004</mods:identifier>
               <mods:identifier type="scopus">2-s2.0-85069965152</mods:identifier>
               <mods:identifier type="uri">https://hdl.handle.net/20.500.12105/22822</mods:identifier>
               <mods:identifier type="wos">474917200004</mods:identifier>
               <mods:abstract>Introduction: Since 2015, integrase strand transfer inhibitors (INSTI)-based regimens have been considered as the preferred option for antiretroviral therapy (ART)-naive patients. The main objective of this study was to identify the ART-regimens selected for treatment-naive patients during 2015 in two tertiary hospitals, determine the rate of virological failure at 24 and 48 weeks, and compare the results with those of previous years (2012-2014). Material and methods: Four-year retrospective study. Adult ART-naive patients who had started treatment between 2012 and 2015 were selected. Clinical data, laboratory tests performed, and ART selected were recorded. Results: A total of 536 patients were included, 137 from 2015 and 399 from 2012-2014. The most common ART regimens prescribed in 2015, compared to 2012-2014, were INSTI-based regimens (68.6% vs. 4.8%), followed by non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (20.4% vs. 52.8%) and PI-based regimens (10.9% vs. 42.5%). Most patients received a single-tablet regimen (78.8% vs. 51.9%). In 2015, 72.3% of patients had a viral load (VL) &lt; 50 copies/ml at week 24 and 83.9% at week 48, compared to 55.1% and 74.7%, respectively, in 2012-2014. During the 48-week follow-up, the ART regimen was changed in 22.6% of patients in 2015 and 29.3% in 2012-2014. The main reason was simplification (45.2% vs. 22.2%) followed by side effects (25.8% vs. 38.5%). Conclusions: In 2015, INSTI-based regimens were prescribed in nearly 70% of ART-naive patients. This change in trend in the starting ART regimen results in a greater number of patients achieving a VL &lt; 50 copies/ml at weeks 24 and 48 and in a reduction in ART changes due to adverse effects.</mods:abstract>
               <mods:language>
                  <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
               </mods:language>
               <mods:accessCondition type="useAndReproduction"/>
               <mods:subject>
                  <mods:topic>Adult</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>anti-HIV agents</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>HIV infections</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Treatment outcome</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Viral load</mods:topic>
               </mods:subject>
               <mods:titleInfo>
                  <mods:title>Effectiveness of antiretroviral therapy in treatment-naive patients. Results at 24 and 48 weeks</mods:title>
               </mods:titleInfo>
               <mods:genre>research article</mods:genre>
            </mods:mods>
         </xmlData>
      </mdWrap>
   </dmdSec>
   <structMap LABEL="DSpace Object" TYPE="LOGICAL">
      <div TYPE="DSpace Object Contents" ADMID="DMD_20.500.12105_22822"/>
   </structMap>
</mets></metadata></record></GetRecord></OAI-PMH>